Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials

Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Ce...

Full description

Saved in:
Bibliographic Details
Main Authors: Lina Tao, Xiaoyu Qu, Yue Zhang, Yanqing Song, Si-xi Zhang
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2019/3192351
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832563215603597312
author Lina Tao
Xiaoyu Qu
Yue Zhang
Yanqing Song
Si-xi Zhang
author_facet Lina Tao
Xiaoyu Qu
Yue Zhang
Yanqing Song
Si-xi Zhang
author_sort Lina Tao
collection DOAJ
description Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.
format Article
id doaj-art-55a918ae4d8b457abac622e6118d0a13
institution Kabale University
issn 2291-2789
2291-2797
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Canadian Journal of Gastroenterology and Hepatology
spelling doaj-art-55a918ae4d8b457abac622e6118d0a132025-02-03T01:20:37ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972019-01-01201910.1155/2019/31923513192351Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled TrialsLina Tao0Xiaoyu Qu1Yue Zhang2Yanqing Song3Si-xi Zhang4Department of Pharmacy, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Pharmacy, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Pharmacy, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Pharmacy, The First Hospital of Jilin University, Changchun 130021, ChinaDepartment of Pharmacy, The First Hospital of Jilin University, Changchun 130021, ChinaBackground. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.http://dx.doi.org/10.1155/2019/3192351
spellingShingle Lina Tao
Xiaoyu Qu
Yue Zhang
Yanqing Song
Si-xi Zhang
Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
Canadian Journal of Gastroenterology and Hepatology
title Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
title_full Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
title_fullStr Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
title_short Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials
title_sort prophylactic therapy of silymarin milk thistle on antituberculosis drug induced liver injury a meta analysis of randomized controlled trials
url http://dx.doi.org/10.1155/2019/3192351
work_keys_str_mv AT linatao prophylactictherapyofsilymarinmilkthistleonantituberculosisdruginducedliverinjuryametaanalysisofrandomizedcontrolledtrials
AT xiaoyuqu prophylactictherapyofsilymarinmilkthistleonantituberculosisdruginducedliverinjuryametaanalysisofrandomizedcontrolledtrials
AT yuezhang prophylactictherapyofsilymarinmilkthistleonantituberculosisdruginducedliverinjuryametaanalysisofrandomizedcontrolledtrials
AT yanqingsong prophylactictherapyofsilymarinmilkthistleonantituberculosisdruginducedliverinjuryametaanalysisofrandomizedcontrolledtrials
AT sixizhang prophylactictherapyofsilymarinmilkthistleonantituberculosisdruginducedliverinjuryametaanalysisofrandomizedcontrolledtrials